Related Experiment Video
Updated: Jul 10, 2026
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
Asma Komal1, Mamoona Noreen2, Attalla F El-Kott3,4
1Department of Zoology, The Women University Multan, Multan, Pakistan.
Abstract:
Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the last few decades together with its agonists due to their contribution to cancer regression. These agonists undeniably have some shared characteristics such as mimicking dsRNA but pathways through which they exhibit antitumor properties are relatively diverse. In this review, three widely studied agonists RGC100, ARNAX, and poly-IC are discussed along with their structural and physiochemical differences including the signaling cascades through which they exert their actions. Comparison has been made to identify the finest agonist with maximum effectivity and the least side effect profile.
Insights
Toll-like receptor 3 (TLR3) agonists like RGC100, ARNAX, and poly-IC show promise in cancer regression. This review compares their diverse antitumor pathways and properties to find the most effective and safest option.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Toll-like receptors 3 (TLR3) are crucial in innate immunity and have been investigated for their role in cancer regression.
- TLR3 agonists, which mimic double-stranded RNA (dsRNA), represent a promising therapeutic strategy for various cancers.
- Despite shared characteristics, these agonists exhibit diverse mechanisms of action and signaling pathways.
Purpose of the Study:
- To review and compare three widely studied TLR3 agonists: RGC100, ARNAX, and poly-IC.
- To analyze the structural and physiochemical differences among these agonists.
- To evaluate their distinct signaling cascades and antitumor properties.
Main Methods:
- Literature review of studies on RGC100, ARNAX, and poly-IC.
- Comparative analysis of agonist structures, physicochemical properties, and signaling pathways.
- Assessment of reported efficacy and side effect profiles in preclinical and clinical studies.
Main Results:
- RGC100, ARNAX, and poly-IC share dsRNA-mimicking properties but differ in their molecular structures and physicochemical characteristics.
- Each agonist activates distinct signaling cascades downstream of TLR3, leading to varied immune responses and antitumor effects.
- Preliminary data suggests differences in their therapeutic efficacy and safety profiles, necessitating further investigation.
Conclusions:
- TLR3 agonists offer a versatile platform for cancer immunotherapy, with distinct agents potentially suited for different therapeutic contexts.
- Understanding the nuanced differences in their mechanisms and properties is key to optimizing their clinical application.
- Further research is warranted to identify the optimal TLR3 agonist with maximal antitumor efficacy and minimal adverse effects.
More Related Videos
14:02Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells
Published on: April 9, 2018
06:08Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
Published on: September 22, 2023
